Warberg Asset Management’s Rein Therapeutics RNTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$78K Sell
96,000
-3,000
-3% -$2.46K 0.01% 156
2026
Q2
$101K Buy
+99,000
New +$120K 0.02% 138
2025
Q4
– Sell
-11,000
Closed -$12.6K – 229
2025
Q3
$12.6K Buy
+11,000
New +$14K ﹤0.01% 166
2024
Q4
– Sell
-10,000
Closed -$35.4K – 239
2024
Q3
$35.4K Sell
10,000
-21,354
-68% -$57.1K 0.01% 146
2024
Q2
$86.2K Buy
+31,354
New +$129K 0.01% 138

Other funds holding RNTX

Warberg Asset Management's RNTX Position: Q3 2026 in Review

Warberg Asset Management reduced its Rein Therapeutics (RNTX) stake by 3% in Q3 2026, selling an estimated $2.46K and leaving 96,000 shares worth $78K. The position accounts for 0.01% of the portfolio, ranked #156.

Warberg Asset Management first reported a position in RNTX in Q2 2024 and has held it in 5 quarters since. The position peaked at $101K in Q2 2026. 63 funds tracked by Wall St. Rank hold RNTX as of Q3 2026.

  • Warberg Asset Management held 96,000 shares of Rein Therapeutics worth $78K as of Q3 2026.
  • Warberg Asset Management sold 3,000 Rein Therapeutics shares in Q3 2026, an estimated $2.46K.
  • Rein Therapeutics made up 0.01% of Warberg Asset Management's portfolio in Q3 2026, its #156 holding.
  • Warberg Asset Management first reported a position in Rein Therapeutics in Q2 2024 and has held it in 5 quarters since.
  • Warberg Asset Management's Rein Therapeutics position peaked at $101K in Q2 2026.
  • 63 funds tracked by Wall St. Rank held Rein Therapeutics as of Q3 2026.

Based on Warberg Asset Management's 13F filing for Q3 2026, filed 2 Nov 2026.